HanAll Biopharma Co., Ltd. - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

HanAll Biopharma Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'HanAll Biopharma Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the HanAll Biopharma Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of HanAll Biopharma Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of HanAll Biopharma Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of HanAll Biopharma Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the HanAll Biopharma Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate HanAll Biopharma Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of HanAll Biopharma Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the HanAll Biopharma Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of HanAll Biopharma Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of HanAll Biopharma Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of HanAll Biopharma Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
HanAll Biopharma Co., Ltd. Snapshot 6
HanAll Biopharma Co., Ltd. Overview 6
Key Information 6
Key Facts 6
HanAll Biopharma Co., Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
HanAll Biopharma Co., Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
HanAll Biopharma Co., Ltd. - Pipeline Products Glance 13
HanAll Biopharma Co., Ltd. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
HanAll Biopharma Co., Ltd. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
HanAll Biopharma Co., Ltd. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
HanAll Biopharma Co., Ltd. - Unknown Stage Pipeline Products 18
Unknown Products/Combination Treatment Modalities 18
HanAll Biopharma Co., Ltd. - Drug Profiles 19
(atorvastatin calcium + losartan potassium) 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
(chlorthalidone + telmisartan) 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
cobamamide 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
(candesartan + amlodipine besylate) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(simvastatin Immediate Release + amlodipine maleate Delayed Release) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
HL-143 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
(amlodipine besylate + losartan potassium) 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
(aspirin + clopidogrel) 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
(metformin + candesartan) 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
(simvastatin + losartan potassium) 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
bosentan CR 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
HL-032 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
HL-036 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
HL-156Can 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
HL-156Fib 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
HL-161 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
HL-176 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
HL-177 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
HL-178 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
HL-144 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
HanAll Biopharma Co., Ltd. - Pipeline Analysis 40
HanAll Biopharma Co., Ltd. - Pipeline Products by Target 40
HanAll Biopharma Co., Ltd. - Pipeline Products by Route of Administration 42
HanAll Biopharma Co., Ltd. - Pipeline Products by Molecule Type 43
HanAll Biopharma Co., Ltd. - Pipeline Products by Mechanism of Action 44
HanAll Biopharma Co., Ltd. - Recent Pipeline Updates 46
HanAll Biopharma Co., Ltd. - Dormant Projects 48
HanAll Biopharma Co., Ltd. - Discontinued Pipeline Products 53
Discontinued Pipeline Product Profiles 53
HL-015 53
HL-016 53
Loratadine ODT 53
HanAll Biopharma Co., Ltd. - Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56

List of Tables
HanAll Biopharma Co., Ltd., Key Information 6
HanAll Biopharma Co., Ltd., Key Facts 6
HanAll Biopharma Co., Ltd. - Pipeline by Indication, 2014 8
HanAll Biopharma Co., Ltd. - Pipeline by Stage of Development, 2014 10
HanAll Biopharma Co., Ltd. - Monotherapy Products in Pipeline, 2014 11
HanAll Biopharma Co., Ltd. - Combination Treatment Modalities in Pipeline, 2014 12
HanAll Biopharma Co., Ltd. - Phase III, 2014 13
HanAll Biopharma Co., Ltd. - Phase II, 2014 14
HanAll Biopharma Co., Ltd. - Phase I, 2014 15
HanAll Biopharma Co., Ltd. - Preclinical, 2014 16
HanAll Biopharma Co., Ltd. - Discovery, 2014 17
HanAll Biopharma Co., Ltd. - Unknown, 2014 18
HanAll Biopharma Co., Ltd. - Pipeline by Target, 2014 41
HanAll Biopharma Co., Ltd. - Pipeline by Route of Administration, 2014 42
HanAll Biopharma Co., Ltd. - Pipeline by Molecule Type, 2014 43
HanAll Biopharma Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 45
HanAll Biopharma Co., Ltd. - Recent Pipeline Updates, 2014 46
HanAll Biopharma Co., Ltd. - Dormant Developmental Projects,2014 48
HanAll Biopharma Co., Ltd. - Discontinued Pipeline Products, 2014 53
HanAll Biopharma Co., Ltd., Other Locations 54